


## Tinoridine

Cat. No.:	HY-W032848
CAS No.:	24237-54-5
Molecular Formula:	C <sub>17</sub> H <sub>20</sub> N <sub>2</sub> O <sub>2</sub> S
Molecular Weight:	316.42
Target:	COX
Pathway:	Immunology/Inflammation
Storage:	-20°C, protect from light
	* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (395.04 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.1604 mL	15.8018 mL	31.6036 mL
	5 mM	0.6321 mL	3.1604 mL	6.3207 mL
	10 mM	0.3160 mL	1.5802 mL	3.1604 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Tinoridine (Y-3642) is an orally active non-steroidal anti-inflammatory agent with potent antiperoxidative ability and radical scavenger activity. Tinoridine acts function by inhibiting COX enzyme, involves in hepatotoxicity inhibition. <sup>[1][2][3]</sup>

#### In Vitro

Tinoridine (10-100 μM) exerts effect on stability of rat liver and kidney lysosomes, and liver parenchymal cells<sup>[3]</sup>. Tinoridine (1, 10, and 100 μM; 30 min) inhibits spontaneous release of acid phosphatase from liver lysosomes in vitro<sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Tinoridine (100 mg/kg; p.o.; single dose) inhibits CCl<sub>4</sub> hepatotoxicity in rats, with a strong control of the CCl<sub>4</sub>-induced enzyme activities<sup>[2]</sup>. Tinoridine (100 mg/kg; i.p.; single dose) protects the stability of rat liver and kidney lysosomes in vivo<sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (180-220 g) <sup>[2]</sup>
Dosage:	100 mg/kg

---

Administration:	Oral gavage; single dose; 1 hour before CCl <sub>4</sub> (i.p.; 0.25 mL/kg) treatment
Result:	Inhibited the CCl <sub>4</sub> -induced enzyme activities increase of serum glutamic-oxaloacetic transaminase and glutamic-pyruvic transaminase, and also rescued the liver microsomal cytochrome P-450 and glucose-6-phosphatase activities.

---

## REFERENCES

---

- [1]. da Cruz RMD, et al. Thiophene-Based Compounds with Potential Anti-Inflammatory Activity. *Pharmaceuticals (Basel)*. 2021 Jul 19;14(7):692.
- [2]. Yasuda H, et al. The protective effect of tinoridine against carbon tetrachloride hepatotoxicity. *Toxicol Appl Pharmacol*. 1980 Mar 15;52(3):407-13.
- [3]. Goto K, et al. Effect of tinoridine on stability of rat liver and kidney lysosomes, and liver parenchymal cells. *Biochem Pharmacol*. 1977 Jan 1;26(1):11-8.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA